Cabot scores 18x return on MedicX sale
Cabot Square Capital has sold healthcare investment manager MedicX Group to Octopus Investments, generating an 18x return on invested capital.
For Octopus, the deal has enabled the investor to scale up its healthcare business.
The firm completed the investment through its parent company Octopus Capital. The transaction takes Octopus's funds under management to £4.7m.
Cabot Square supported the creation of MedicX in 2004 in order to capitalise on the emergence of healthcare property as an institutional asset class.
Today, MedicX is a UK healthcare investment manager with £900m of funds under management across its LSE listed MedicX Fund (MXF) and two private closed-ended funds. The company also operates a proprietary origination platform, which develops healthcare properties for the funds it manages.
The company employs 30 people throughout the UK.
Keith Maddin is a partner at Cabot Square. Mike Adams is CEO of MedicX and David Staples is chairman of MedicX Fund. Simon Rogerson is CEO of Octopus.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









